CLS Therapeutics
Pre-clinicalCLS Therapeutics is translating the emerging biology of circulating nucleic acids into transformative gene therapies for cancer. Founded by scientists and biotech entrepreneurs, the company is advancing its lead program, CLS-014, a novel AAV vector encoding a hyperactive DNase I enzyme, to clean pathogenic cfDNA from patients' blood. With a team of experts in cfDNA research, gene therapy, and oncology, CLS is focused on treating gastrointestinal cancers and has engaged in strategic collaborations to advance its platform.
AI Company Overview
CLS Therapeutics is translating the emerging biology of circulating nucleic acids into transformative gene therapies for cancer. Founded by scientists and biotech entrepreneurs, the company is advancing its lead program, CLS-014, a novel AAV vector encoding a hyperactive DNase I enzyme, to clean pathogenic cfDNA from patients' blood. With a team of experts in cfDNA research, gene therapy, and oncology, CLS is focused on treating gastrointestinal cancers and has engaged in strategic collaborations to advance its platform.
Technology Platform
AAV vector-based gene therapy platform designed to deliver engineered enzymes (e.g., hyperactive DNase I) into the bloodstream to degrade circulating cell-free DNA (cfDNA), a pro-tumorigenic factor in cancer.
Opportunities
Risk Factors
Competitive Landscape
CLS Therapeutics is a pioneer in the direct therapeutic degradation of cfDNA, with few, if any, direct competitors. It competes indirectly with the entire spectrum of oncology therapeutics. Its main differentiation is its first-in-class mechanism targeting a systemic driver of cancer progression rather than the tumor cell itself, which could offer a complementary approach to existing treatments.
Company Info
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile